Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Inclusion Criteria:

• Advanced solid malignancy
• Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

• Radiotherapy within 3 weeks of the start of treatment
• Investigational product within the last 3 weeks
• Systemic cytotoxic anti-cancer therapy within the last 3 weeks
• Any significant clinical disorder that makes it undesirable for the patient to participate